A fraction from Escherichia coli with anti-Aspergillus properties
- 1 April 2005
- journal article
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 54 (4) , 375-379
Abstract
The products of various strains of Escherichia coli (BL21, DH5α, HB101 and XL Blue) were investigated for antimycotic properties using pathogenic isolates of Aspergillus. Co-culture experiments revealed that E. coli strains exhibited variable activity against Aspergillus fumigatus. The lysates prepared from DH5α, HB101 and XL Blue strains of E. coli showed inhibitory activity against A. fumigatus in the protein concentration range of 62.50 to 250.00 μg ml−1. The highest activity was seen in the lysate of BL21, which inhibited the growth of A. fumigatus and Aspergillus flavus completely at a concentration of 31.25 μg protein ml−1. The MIC of BL21 lysate against Aspergillus niger was found to be 62.50 μg ml−1. The in vitro toxicity of BL21 lysate was evaluated using a haemolytic assay. A BL21 lysate protein concentration of 1250.00 μg ml−1 was found to be nontoxic to human erythrocytes. The standard drug amphotericin B lysed 100 % of erythrocytes at a concentration of 37.50 μg ml−1. SDS-PAGE showed the presence of at least 15 major proteins in the lysate of BL21. Ion-exchange chromatography resolved the BL21 lysate into five fractions and fraction III was found to be endowed with anti-Aspergillus properties. The MIC of this fraction was found to be 3.90 μg ml−1. Further work on the purification of the active molecule and its characterization is in progress.Keywords
This publication has 34 references indexed in Scilit:
- Purification and Characterization of Chitosanase from Bacillus sp. Strain KCTC 0377BP and Its Application for the Production of Chitosan OligosaccharidesApplied and Environmental Microbiology, 2004
- Isolation of peptides of the brevinin‐1 family with potent candidacidal activity from the skin secretions of the frog Rana boyliiChemical Biology & Drug Design, 2003
- Production by Bacillus pumilus (MSH) of an antifungal compound that is active against Mucoraceae and Aspergillus species: preliminary reportJournal of Medical Microbiology, 2003
- New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with CancerThe Oncologist, 2000
- In Vitro Antifungal Activity and Cytotoxicity of a Novel Membrane-Active PeptideAntimicrobial Agents and Chemotherapy, 1999
- Antibacterial and antifungal activity of small protein of Indigofera oblongifolia leavesJournal of Ethnopharmacology, 1999
- Granulocyte Colony-Stimulating Factor and Azole Antifungal Therapy in Murine Aspergillosis: Role of Immune SuppressionAntimicrobial Agents and Chemotherapy, 1998
- Probiotische Therapie einer pseudomembranösen Kolitis: Kombinatiion aus intestinaler Lavage und oraler Gabe von Escherichia coliDMW - Deutsche Medizinische Wochenschrift, 1998
- Interactions of antibiotics of the iturin group with human erythrocytesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1986
- Maturation of the head of bacteriophage T4Journal of Molecular Biology, 1973